Zealand Pharma

Major Shareholding Notification • Jun 12, 2015

Copenhagen, 2015-06-12 17:09 CEST (GLOBE NEWSWIRE) -- 12 June 2015 – Zealand
Pharma (“Zealand”) (Nasdaq Copenhagen: ZEAL) has today received a major
shareholder notification from Legg Mason, Inc., 100 International Drive, 9th
Fl., Baltimore, Maryland 21202, the United States (CVR-no. US-D01223502). Legg
Mason, Inc. is the parent company of Royce & Associates LLC, manager of a list
of funds and trusts.

Pursuant to Section 29 of the Danish Securities Act, cf. executive order no.
668 of 25 June 2012 on major shareholders and the Danish Companies Act section
55, cf. section 56, Zealand has been notified that Legg Mason, Inc. control
voting rights on 1,198,550 shares, corresponding to 5.10% of the total voting
rights in Zealand.

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations & Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen,
Denmark. Zealand has leading expertise in the discovery, design and development
of novel peptide medicines and
possesses in-house competences in clinical trial design and management with a
therapeutic focus on metabolic diseases
and acute care indications. The company is advancing a proprietary pipeline of
novel medicines alongside a partnered
product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes,
is marketed globally (ex-US) as Lyxumia® and is in Phase III development as a
single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory filing for Lyxumia® is planned for Q3 2015 and filing for LixiLan is
planned for Q4 2015 in the US and Q1 2016 in Europe.

Zealand’s proprietary pipeline includes danegaptide (prevention of Ischemic
Reperfusion Injury) and two stable glucagon
products, ZP4207 (one for treatment of severe hypoglycemia and the other for
mild to moderate hypoglycemia) as well
as several preclinical peptide therapeutics. Partnering represents an important
component of strategy to leverage in-house expertise, share development risk in
large clinical trials, provide funding and commercialize the company’s
products. Zealand currently has global license agreements and partnerships with
Sanofi, Helsinn Healthcare and
Boehringer Ingelheim.

For further information: www.zealandpharma.com Follow us on Twitter
@ZealandPharma